Ko et al. demonstrated that plerixafor-functionalized nanomaterials significantly improved drug delivery to CXCR4-overexpressing tumors, with enhanced tumor accumulation and photothermal anticancer efficacy, suggesting potential applications in CXCR4-targeted nanotherapy (Ko et al., 2018). This evidence concerns the gene CXCR4 and neoplasm.